SpectraCure AB (DE:2OK)
FRANKFURT:2OK
Want to see DE:2OK full AI Analyst Report?
2OK Stock Chart & Stats
€0.01
€0.03(15.76%)
At close: 4:00 PM EST
€0.01
€0.03(15.76%)
Day’s Range― - ―
52-Week Range€0.00 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)2.59K
Market Cap
€4.49M
Enterprise Value€24.06M
Total Cash (Recent Filing)€13.53M
Total Debt (Recent Filing)€3.01M
Price to Earnings (P/E)―
Beta-82.94
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding570,602,840
10 Day Avg. Volume4,037
30 Day Avg. Volume2,593
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Differentiated IDOSE PlatformThe IDOSE platform’s fiber-optic delivery combined with real-time monitoring creates a durable technical differentiation for interstitial PDT. That capability to plan and control light dose can improve clinical outcomes, support regulatory pathways, and enable expansion into adjacent tumor indications over time.
Low Financial LeverageA conservative leverage profile reduces near-term insolvency risk and gives strategic optionality to fund R&D or trials without heavy interest burdens. Low debt provides a more stable platform for multi-stage clinical development and potential partnership negotiations over the next several quarters.
Focused Clinical Niche (prostate PDT)A clear initial indication—prostate cancer—provides a defined clinical and regulatory pathway and a concentrated go-to-market plan. Minimally invasive PDT aligns with structural trends toward less invasive oncology care, offering a repeatable model that can be leveraged into other localized tumor markets.
Bears Say
Minimal Or Near-zero RevenueThe absence of meaningful revenue means the company remains pre-commercial and dependent on external financing. Without scalable sales, operating costs cannot be absorbed, extending the timeline to self-sustaining cash generation and increasing execution risk over multiple funding cycles.
Accelerating Cash BurnRapidly worsening negative free cash flow materially shortens operational runway and raises the likelihood of recurring capital raises. This structural cash burn pressures strategic choices, dilutes shareholders upon financing, and can constrain the timing and scale of clinical or commercial investment.
Worsening Net LossesA large widening of net losses indicates operating expenses growing faster than any revenue prospects, degrading the equity base and increasing funding needs. Persistent and escalating losses raise long-term viability concerns absent clear progress to commercialization or material partnerships.
2OK FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is €4.49M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is May 27, 2026 which is in 3 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 570,602,840 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in DE:2OK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.